[1]罗士欢,刘红军,杨树琳,等.北京某高校社区绝经后期髋关节骨质疏松症患者的影响因素分析[J].医学信息,2025,38(03):80-84.[doi:10.3969/j.issn.1006-1959.2025.03.015]
　LUO Shihuan,LIU Hongjun,YANG Shulin,et al.Analysis of Influencing Factors of Postmenopausal Patients with Hip Osteoporosis in a University Community in Beijing[J].Journal of Medical Information,2025,38(03):80-84.[doi:10.3969/j.issn.1006-1959.2025.03.015]
点击复制

北京某高校社区绝经后期髋关节骨质疏松症患者的影响因素分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年03期
页码:
80-84
栏目:
论著
出版日期:
2025-02-01

文章信息/Info

Title:
Analysis of Influencing Factors of Postmenopausal Patients with Hip Osteoporosis in a University Community in Beijing
文章编号:
1006-1959（2025）03-0080-05
作者:
罗士欢; 刘红军; 杨树琳; 夏蓉晖; 王俊杰
北京交通大学医院内科，北京 100044
Author(s):
LUO Shihuan;  LIU Hongjun;  YANG Shulin;  XIA Ronghui;  WANG Junjie
Department of Internal Medicine, University Hospital of Beijing Jiaotong Universityl, Beijing 100044, China
关键词:
绝经后期; 骨质疏松症; 影响因素; 典型相关分析
Keywords:
Postmenopausal period;  Osteoporosis;  Influencing factors;  Canonical correlation analysis
分类号:
R681
DOI:
10.3969/j.issn.1006-1959.2025.03.015
文献标志码:
A
摘要:
目的 了解某高校社区绝经后期女性发生髋关节骨质疏松的影响因素，为早期预防髋关节骨质疏松性骨折提供依据。方法 选择2021年1月-2023年1月在北京交通大学医院体检的362例绝经后期女性为研究对象，采用双能X线骨密度仪（DXA）测量全髋的骨密度，根据骨密度（BMD）的结果分为骨质疏松症组和非骨质疏松症组。观察两组甲状腺激素及性激素指标水平，分析绝经后期女性发生髋关节骨质疏松症的危险因素。结果 362例绝经后期女性中有116例发生了髋关节骨质疏松，髋关节骨质疏松发生率为32.04%（116/362）；绝经年限和体重指数是与髋关节骨质疏松症相关的重要因素；骨质疏松症组和未发生骨质疏松症组的促甲状腺激素（TSH）、雌二醇（E2）水平比较，差异有统计学意义（P＜0.05）；不同TSH分组的BMD比较，差异有统计学意义（P＜0.05），亚临床甲亢组BMD最低；多因素Logistic回归分析结果显示吸烟、绝经年限、尿酸（UA）、TSH、E2是绝经后期髋关节骨质疏松症的影响因素。结论 绝经后期女性髋关节骨质疏松症需要引起关注，除了双能X线骨密度仪（DXA）、骨质疏松风险评估问卷，TSH与E2水平也可用于评估骨质疏松症发生风险，值得临床应用。
Abstract:
Objective To understand the influencing factors of postmenopausal women with hip osteoporosis in a university community, and to provide evidence for early prevention of osteoporotic hip fracture. Methods A total of 362 postmenopausal women who underwent physical examination in Beijing Jiaotong University Hospital from January 2021 to January 2023 were selected as the study subjects. The bone mineral density of the total hip was measured by dual-energy X-ray absorptiometry (DXA). According to the results of bone mineral density (BMD), they were divided into osteoporosis group and non-osteoporosis group. The levels of thyroid hormones and sex hormones in the two groups were observed, and the risk factors of hip osteoporosis in postmenopausal women were analyzed. Results Among the 362 postmenopausal women, 116 had hip osteoporosis, and the incidence of hip osteoporosis was 32.04% (116/362). Menopause years and body mass index were important factors associated with hip osteoporosis. There were significant differences in the levels of thyroid stimulating hormone (TSH) and estradiol (E2) between the osteoporosis group and the non-osteoporosis group (P<0.05). There was significant difference in BMD among different TSH groups (P<0.05), and the BMD of subclinical hyperthyroidism group was the lowest. Multivariate logistic regression analysis showed that smoking, years of menopause, uric acid (UA), TSH and E2 were the influencing factors of hip osteoporosis in postmenopausal women. Conclusion Hip osteoporosis in postmenopausal women needs our attention. In addition to dual-energy X-ray absorptiometry (DXA) and osteoporosis risk assessment questionnaire, TSH and E2 levels can also be used to assess the risk of osteoporosis, which is worthy of clinical application.

参考文献/References:

[1]中华医学会骨质疏松和骨矿盐疾病分会.维生素D及其类似物临床应用共识[J].中华骨质疏松和骨矿盐疾病杂志,2018,11(1):1-19.[2]赵春锋,杨焕民.围绝经期妇女性激素水平与骨质疏松症的相关性研究[J].中国性科学,2020,29(11):88-91.[3]Hao W,Gong L,Xue F.The Efficacy and Safety of Modified Xiaoyao San for Perimenopausal Syndrome (PMS): A Systematic Review and Meta-Analysis[J].Journal of Biosciences and Medicines,2019,7(4):60-72.[4]Batmaz,Ibrahim,Sariyildiz,et al.A Case of Spondyloepiphyseal Dysplasia Tarda Coexisting With Osteoporosis and Mimicking Spondyloarthropathy[J].Türkiye Fiziksel Tip Ve Rehabilitasyon Dergisi,2018,59(3):260-263.[5]Zhu H,Jiang J,Wang Q,et al.Associations between ERα/β gene polymorphisms and osteoporosis susceptibility and bone mineral density in postmenopausal women: a systematic review and meta-analysis[J].BMC Endocr Disord,2018,18(1):11.[6]中国老年学和老年医学学会骨质疏松分会妇产科专家委员会与围绝经期骨质疏松防控培训部.围绝经期和绝经后妇女骨质疏松防治专家共识[J].中国临床医生杂志,2020,48(8):903-908.[7]中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2022)[J].中华骨质疏松和骨矿盐疾病杂志,2022,15(6):573-611.[8]中国肥胖问题工作组.中国成人超重和肥胖症预防与控制指南(节录)[J].营养学报,2004(1):1-4.[9]中华医学会内分泌学分会.成人甲状腺功能减退症诊治指南[J].中华内分泌代谢杂志,2017,33(2):167-180.[10]中华医学会老年医学分会老年内分泌代谢疾病学组,中华医学会内分泌学分会甲状腺学组.中国老年人甲状腺疾病诊疗专家共识(2021)[J].中华内分泌代谢杂志,2021,37(5):399-418.[11]唐迅,张杜丹,何柳,等.China-PAR模型在北方农村人群中预测动脉粥样硬化性心血管疾病发病风险的应用[J].北京大学学报(医学版),2017,49(3):439-445.[12]中华医学会糖尿病学分会.中国2型糖尿病防治指南（2020年版）[J].中华糖尿病杂志,2021,13(4):315-409.[13]杨志宏,张小妮,王小娟,等.血清25(OH)D3、超敏C反应蛋白水平与老年2型糖尿病合并骨质疏松的相关性分析[J].标记免疫分析与临床,2019,26(3):502-505,510.[14]Fistarol M,Rezende CR,Figueiredo Campos AL,et al.Time since menopause, but not age, is associated with increased risk of osteoporosis[J].Climacteric,2019,22(5):523-526.[15]Shayganfar A,Ebrahimian S,Masjedi M,et al.A study on bone mass density using dual energy X-ray absorptiometry: Does high body mass index have protective effect on bone density in obese patients?[J].J Res Med Sci,2020,25:4.[16]黄彬彬,赵秀欣.某高校4056例教职工骨密度流行病学调查分析[J].中国骨质疏松杂志,2018,24(4):500-502,513.[17]袁仪珮,汤旭磊,刘靖芳,等.兰州市社区居民亚临床甲状腺功能减退症患者骨密度变化及影响因素[J].中国骨质疏松杂志,2020,26(10):1533-1537.[18]尹飞,李志红,郭淑芹,等.绝经后2型糖尿病患者亚临床甲状腺功能减退症与骨质疏松症的相关性研究[J].临床内科杂志,2016,33(9):605-607.[19]毛幸,楼超,周晓明.围绝经期骨质疏松与血清维生素D、雌激素水平的相关性分析[J].中国妇幼保健,2019,34(17):4002-4005.[20]周艳,刘晓健,郑玉民,等.北京某高校教职工骨密度与血糖、血脂及血尿酸的相关性[J].中日友好医院学报,2021,35(4):229-231.[21]Li HZ,Chen Z,Hou CL,et al.Uric Acid Promotes Osteogenic Differentiation and Inhibits Adipogenic Differentiation of Human Bone Mesenchymal Stem Cells[J].J Biochem Mol Toxicol,2015,29(8):382-387.[22]徐秀兰,魏莉莉,沙玉芳.慢性饮酒、吸烟与骨质疏松的相关性研究[J].临床内科杂志,2013,30(7):478-480.

相似文献/References:

[1]汪钦生,邵 敏,姜 涛.绝经后妇女中骨质疏松患者血清钙磷、骨代谢指标与BMD的关系[J].医学信息,2019,32(04):1.[doi:10.3969/j.issn.1006-1959.2019.04.001]
　WANG Qin-sheng,SHAO Min,JIANG Tao.Relationship between Serum Calcium,Phosphorus and Bone Metabolism Markers and BMD in Postmenopausal Women with Osteoporosis[J].Journal of Medical Information,2019,32(03):1.[doi:10.3969/j.issn.1006-1959.2019.04.001]
[2]李 红,孔令泉,吴凯南.乳腺癌相关骨质疏松症的发病机制及防治[J].医学信息,2020,33(07):36.[doi:10.3969/j.issn.1006-1959.2020.07.012]
　LI Hong,KONG Ling-quan,WU Kai-nan.Pathogenesis and Prevention of Breast Cancer Associated Osteoporosis[J].Journal of Medical Information,2020,33(03):36.[doi:10.3969/j.issn.1006-1959.2020.07.012]
[3]刘 纳,李玉兰,许明芳,等.2型糖尿病临床期肾病与骨密度及骨代谢标记物的相关性研究[J].医学信息,2020,33(08):70.[doi:10.3969/j.issn.1006-1959.2020.08.023]
　LIU Na,LI Yu-lan,XU Ming-fang,et al.Study on the Relationship Between Bone Mineral Density and Bone Metabolism Markers in Stage IV Nephropathy of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2020,33(03):70.[doi:10.3969/j.issn.1006-1959.2020.08.023]
[4]石耀武,陶宝琛,张宏蕾.西安地区骨质疏松症的影响因素及中医证型分布[J].医学信息,2020,33(11):136.[doi:10.3969/j.issn.1006-1959.2020.11.043]
　SHI Yao-wu,TAO Bao-chen,ZHANG Hong-lei.Influencing Factors of Osteoporosis in Xi’an and Distribution of TCM Syndromes[J].Journal of Medical Information,2020,33(03):136.[doi:10.3969/j.issn.1006-1959.2020.11.043]
[5]米尔阿地力·麦麦提依明,阿卜杜萨拉木·亚克甫,沈志敏.骨质疏松对全膝关节置换术后康复的影响[J].医学信息,2021,34(09):99.[doi:10.3969/j.issn.1006-1959.2021.09.026]
　Mieradili·Maimaitiyiming,Abudusalamu·Yakepu,SHEN Zhi-min.Effect of Osteoporosis on Rehabilitation After Total Knee Arthroplasty[J].Journal of Medical Information,2021,34(03):99.[doi:10.3969/j.issn.1006-1959.2021.09.026]
[6]李泽芹.降钙素联合阿仑膦酸盐治疗原发性骨质疏松症有效性评价[J].医学信息,2021,34(17):154.[doi:10.3969/j.issn.1006-1959.2021.17.041]
　LI Ze-qin.Evaluation of the Effectiveness of Calcitonin Combined with Alendronate Sodium in the Treatment of Primary Osteoporosis[J].Journal of Medical Information,2021,34(03):154.[doi:10.3969/j.issn.1006-1959.2021.17.041]
[7]朱道信,罗志环,陈少健,等.唑来膦酸联合骨化三醇对骨质疏松症患者骨密度及骨代谢相关指标的影响[J].医学信息,2021,34(23):162.[doi:10.3969/j.issn.1006-1959.2021.23.049]
　ZHU Dao-xin,LUO Zhi-huan,CHEN Shao-jian,et al.Effect of Zoledronic Acid Combined with Calcitriol on Bone Mineral Density and Bone Metabolism in Patients with Osteoporosis[J].Journal of Medical Information,2021,34(03):162.[doi:10.3969/j.issn.1006-1959.2021.23.049]
[8]冯欢欢.骨质疏松症中医理论研究的文献计量学分析[J].医学信息,2022,35(16):28.[doi:10.3969/j.issn.1006-1959.2022.16.006]
　FENG Huan-huan.Bibliometric Analysis of TCM Theoretical Research on Osteoporosis[J].Journal of Medical Information,2022,35(03):28.[doi:10.3969/j.issn.1006-1959.2022.16.006]
[9]张 宁,夏晓黎,王亚锋,等.慢性阻塞性肺疾病合并骨质疏松症危险因素的Meta分析[J].医学信息,2022,35(24):108.[doi:10.3969/j.issn.1006-1959.2022.24.020]
　ZHANG Ning,XIA Xiao-li,WANG Ya-feng,et al.Meta-analysis of Risk Factors for Chronic Obstructive Pulmonary Disease Complicated with Osteoporosis[J].Journal of Medical Information,2022,35(03):108.[doi:10.3969/j.issn.1006-1959.2022.24.020]
[10]周奕良,毛国庆.基于网络药理学和分子对接技术探讨淫羊藿苷治疗骨质疏松症的作用机制[J].医学信息,2023,36(05):29.[doi:10.3969/j.issn.1006-1959.2023.05.005]
　ZHOU Yi-liang,MAO Guo-qing.The Mechanism of Icariin in the Treatment of Osteoporosis Based on Network Pharmacology and Molecular Docking Technology[J].Journal of Medical Information,2023,36(03):29.[doi:10.3969/j.issn.1006-1959.2023.05.005]

更新日期/Last Update: 1900-01-01